Circular Genomics Expands Advisory Board with Expert Talent

Circular Genomics Strengthens Scientific Advisory Board

Circular Genomics, a pioneer in circular RNA (circRNA) biomarkers dedicated to advancing neurology and psychiatry, has recently bolstered its Scientific Advisory Board (SAB) by welcoming Phyllis Barkman Ferrell, MBA, DrPH. With her extensive background in Alzheimer's disease and dementia research, Ferrell's appointment marks a significant enhancement for the company's mission to revolutionize methods of diagnosis and treatment in the psychiatric and neurological domains.

Welcoming a New Expertise

Phyllis Ferrell is a well-respected figure in the field of neurological conditions with a primary focus on Alzheimer's disease (AD). Her vast experience offers a valuable resource for Circular Genomics, which strives to innovate in the fields of psychiatric and neurological health. According to Nikolaos Mellios, MD, PhD, Chief Scientific Officer of Circular Genomics, "Her deep experience in AD research will be invaluable as we continue to explore innovative solutions for early and accurate diagnosis and treatment of this devastating disease that affects millions of people across the world." These sentiments highlight the critical nature of Ferrell's role in enhancing the company’s scientific approach.

Compelling Experience and Contributions

Phyllis Ferrell comes with a robust background advocating for advances in AD and cognitive impairment. She has played pivotal roles in various esteemed organizations committed to enhancing AD research, such as the Davos Alzheimer Collaborative and the Alzheimer's Drug Discovery Foundation. Her leadership experience extends to significant roles at Eli Lilly & Company, where she was the Global Head of External Engagement for AD for nearly a decade.

Ferrell emphasizes her dedication to improving brain health, stating, "As a passionate advocate for brain health – driven by my own personal experience in my family – it is important for individuals to better understand their mental and brain health to find optimal treatments." This perspective resonates with Circular Genomics' goal of advancing diagnostic techniques and treatments for AD.

Building a Dedicated Advisory Board

Dr. Ferrell joins a distinguished team of experts on the Circular Genomics SAB, which includes several highly regarded leaders in the fields of neurology, psychiatry, and precision medicine. Notable members of the board include:

• Roy Perlis, MD: Director, Center of Experimental Drugs & Diagnostics at Massachusetts General Hospital.
• Madhukar Trivedi, MD: Chief of the Division of Mood Disorders at UT Southwestern Medical Center.
• Carlos Cruchaga, PhD: Professor of Psychiatry and Neurology at Washington University School of Medicine.
• Eleni Tzavara, MD, PhD: Research Director of Translational Psychopharmacology.
• Nikolaos Daskalakis, MD, PhD: Director of the Neurogenomics and Translational Bioinformatics Laboratory.
• Mike Ackerman, MD, PhD: Co-Founder and CBO of Arrivo Bioventures.

About Circular Genomics

Circular Genomics is the leading innovator in developing circular RNA-based precision medicine tools designed for the treatment of psychiatric and neurological conditions. The company utilizes exclusive licenses and groundbreaking technologies to redefine treatment approaches for major depressive disorder, working diligently to tailor optimal treatment protocols that greatly shorten the timeline for validating treatment effectiveness.

By advancing circRNA biomarker research, Circular Genomics is positioned at the forefront of scientific exploration, working towards better understanding and management of complex conditions such as Alzheimer's disease. Their initial offerings include comprehensive assays that enable rapid assessment and personalized treatment methodologies.

Frequently Asked Questions

What is Circular Genomics known for?

Circular Genomics focuses on developing circular RNA-based precision medicine tools and diagnostics aimed at enhancing outcomes in neurology and psychiatry.

Why is Phyllis Ferrell's appointment significant?

Her extensive background in Alzheimer's research will provide critical insights into innovative diagnostic and treatment approaches for neurological health.

What is the goal of Circular Genomics?

The primary goal is to improve the diagnosis and treatment of psychiatric and neurological disorders using advanced circular RNA biomarkers.

Who else is on the Scientific Advisory Board?

The board includes renowned experts such as Roy Perlis, Madhukar Trivedi, Carlos Cruchaga, and others, contributing a wealth of knowledge and experience.

How does Circular Genomics tailor treatment protocols?

By leveraging circRNA biomarker research, the company aims to rapidly assess and individualize treatment plans based on patient-specific data.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.